Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Current Assets (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Current Assets for 4 consecutive years, with $367.9 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 31.42% to $367.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $367.9 million through Dec 2025, down 31.42% year-over-year, with the annual reading at $367.9 million for FY2025, 31.42% down from the prior year.
  • Current Assets for Q4 2025 was $367.9 million at Centessa Pharmaceuticals, up from $307.7 million in the prior quarter.
  • The five-year high for Current Assets was $581.2 million in Q1 2022, with the low at $284.5 million in Q1 2024.
  • Average Current Assets over 4 years is $404.1 million, with a median of $361.7 million recorded in 2024.
  • The sharpest move saw Current Assets skyrocketed 70.96% in 2024, then tumbled 45.87% in 2025.
  • Over 4 years, Current Assets stood at $437.7 million in 2022, then decreased by 28.02% to $315.1 million in 2023, then skyrocketed by 70.24% to $536.4 million in 2024, then crashed by 31.42% to $367.9 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $367.9 million, $307.7 million, and $300.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.